The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1270 articles
The global GLP-1 agonists market is anticipated to reach over USD 260.1 billion by 2034, demonstrating a CAGR of 19.9% during the forecast period. This growth is driven by innovations in diabetes, obesity, and cardiovascular disease treatments, though high costs and administration challenges remain.
Anupam Mittal raised concerns about the potential overuse of drugs like Ozempic for weight loss. He also highlighted the upcoming expiration of key GLP-1 drug patents, possibly leading to market changes.
The idea that Ozempic could treat addictions is gaining traction online, but it's crucial to examine the scientific basis for these claims. While some studies explore its impact on reward mechanisms, the drug's effects on the brain are not fully understood.
This review examines MyStart GLP-1, focusing on its claims of quick access, U.S.-based doctors, and fast delivery. It delves into the program's structure, support system, and overall user experience to provide clarity for those considering this option.
The increasing use of GLP-1 drugs is reshaping the food and beverage industry. Circana's research highlights how retailers and manufacturers can adapt to meet the evolving needs of health-conscious consumers.
A McDonald's employee in Utah experienced an unforeseen side effect after trying the new Grinch fries: a rapid 5-pound weight loss. Her experience, shared online, garnered significant attention, with many users humorously considering trying the fries themselves.
Amanda Bynes recently displayed a noticeably slimmer figure while out in Los Angeles. Bynes has openly discussed her weight-loss journey, which she initiated in June with the help of Ozempic.
2025 saw the approval of several groundbreaking medications, transforming the management of chronic diseases and preventive care. These advancements offer new hope for patients and clinicians alike, addressing critical needs in various medical fields.
With the introduction of new weight-loss and diabetes drugs like Ozempic in India, endocrinologists are emphasizing the need for cautious and medically supervised use. Concerns arise particularly for individuals with a 'thin-fat' phenotype, who may experience adverse effects.
